114703-12-7

Basic information

• Product Name: 7-BROMOQUINAZOLINE-2,4(1H,3H)-DIONE
• Synonyms: 7-BROMOQUINAZOLINE-2,4(1H,3H)-DIONE;7-Bromo-2,4(1H,3H)-quinazolinedione;7-Bromoquinazoline-2,4(1H,3H);7-bromo-1H-quinazoline-2,4-dione
• CAS NO: 114703-12-7
• Molecular Formula: C₈H₅BrN₂O₂
• Molecular Weight: 241.05
• Mol File: 114703-12-7.mol
• Article Data: 12

Chemical Properties

• Melting Point: >300℃
• Appearance: /
• Density: 1.753g/cm³
• Refractive Index: 1.623
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 10.21±0.20(Predicted)
• CAS DataBase Reference: 7-BROMOQUINAZOLINE-2,4(1H,3H)-DIONE(CAS DataBase Reference)
• NIST Chemistry Reference: 7-BROMOQUINAZOLINE-2,4(1H,3H)-DIONE(114703-12-7)
• EPA Substance Registry System: 7-BROMOQUINAZOLINE-2,4(1H,3H)-DIONE(114703-12-7)

Safety Data

• Hazardous Substances Data: 114703-12-7(Hazardous Substances Data)

Usage

General Description

7-Bromoquinazoline-2,4(1H,3H)-dione is a chemical compound with the molecular formula C8H4BrN3O2. It is a quinazoline dione derivative that contains a bromine atom. 7-BROMOQUINAZOLINE-2,4(1H,3H)-DIONE has potential pharmaceutical properties and is used as a building block in the synthesis of various pharmacologically active molecules. Its precise applications and uses include pharmaceutical research and development, and it is also used as an intermediate in the production of other organic compounds. Additionally, 7-Bromoquinazoline-2,4(1H,3H)-dione has potential biological activities and it may have a role in various biochemical processes, although further research is needed to fully understand its potential applications.

InChI:InChI=1/C8H5BrN2O2/c9-4-1-2-5-6(3-4)10-8(13)11-7(5)12/h1-3H,(H2,10,11,12,13)

Upstream product

• 304858-65-9 2-amino-4-bromobenzonitrile 
• 124-38-9 carbon dioxide 
• 20776-50-5 2-amino-4-bromobenzoic acid 
• 57-13-6 urea 
• 135484-83-2 2-amino-4-bromo-benzoic acid methyl ester 
• 917-61-3 sodium isocyanate 
• 65971-74-6 N-(3-bromophenyl)-2-(hydroxyimino)ethanamide 
• 6326-79-0 6-bromoisatin 
• 60-35-5 acetamide 
• 591-19-5 m-Bromoaniline 
• 20776-48-1 2-amino-6-chlorobenzoic acid 

Downstream Products

• 1374203-78-7 4-(3-{2-fluoro-4-[7-(5-methyl-furan-2-yl)4-morpholin-4-yl-quinazolin-2-yl]-phenyl}ureido)dimethyl-benzamide 
• 1374203-80-1 5-(2-(4-(3-(4-(dimethylcarbamoyl)phenyl)ureido)phenyl)-4-morpholino-quinazolin-7-yl)furan-2-carboxylic acid 
• 1374208-57-7 methyl 5-(2-(4-(3-(4-(dimethylcarbamoyl)phenyl)ureido)phenyl)-4-morpholino-quinazolin-7-yl)furan-2-carboxylate 
• 1374203-82-3 4-(3-(4-(7-(5-cyanofuran-2-yl)-4-morpholino-quinazolin-2-yl)-3-fluorophenyl)ureido)-N,N-dimethyl-benzamide 
• 1374203-83-4 4-(3-(4-(7-(5-acetylfuran-2-yl)-4-morpholino-quinazolin-2-yl)phenyl)ureido)-2-fluoro-N,N-dimethyl-benzamide 
• 1374203-87-8 N-(4-(3-(4-(7-(5-methylfuran-2-yl)-4-morpholino-quinazolin-2-yl)phenyl)ureido)phenyl)acetamide 
• 1374203-88-9 1-(4-(7-(5-methylfuran-2-yl)-4-morpholino-quinazolin-2-yl)phenyl)-3-(4-(2-oxopyrrolidin-1-yl)phenyl)urea 
• 1374203-71-0 N,N-dimethyl-4-(3-{4-[4-morpholin-4-yl-7-pyrimidin-5-yl-quinazolin-2-yl]-phenyl}-ureido)-benzamide 
• 959237-68-4 7-bromine-2,4-dichloroquinazoline 
• 1374203-73-2 4-(3-{5-[7-(3-methanesulfonyl-phenyl)-4-morpholin-4-yl-quinazolin-2-yl]-pyridin-2-yl}-ureido)-dimethyl-benzamide 
• 1374208-37-3 4-(2-chloro-7-(3-(methylsulfonyl)phenyl)quinazolin-4-yl)morpholine 
• 1374208-38-4 5-[7-(3-methanesulfonyl-phenyl)-4-morpholin-4-yl-quinazolin-2-yl]-pyridin2-ylamine 
• 1334602-72-0 7-bromo-2,4-bis(4-methoxybenzyloxy)quinazoline 
• 1334602-73-1 2,4-bis(4-methoxybenzyloxy)-7-morpholin-4-ylquinazoline 

Relevant articles and documents

Synthesis, Inhibitory Activity, and in Silico Modeling of Selective COX-1 Inhibitors with a Quinazoline Core

Selective cyclooxygenase-1 (COX-1) inhibition has got into the spotlight with the discovery of COX-1 upregulation in various cancers and the cardioprotective role of COX-1 in control of thrombocyte aggregation. Yet, COX-1-selective inhibitors are poorly explored. Thus, three series of quinazoline derivatives were prepared and tested for their potential inhibitory activity toward COX-1 and COX-2. Of the prepared compounds, 11 exhibited interesting COX-1 selectivity, with 8 compounds being totally COX-1-selective. The IC50 value of the best quinazoline inhibitor was 64 nM. The structural features ensuring COX-1 selectivity were elucidated using in silico modeling.

[TBDH][HFIP] ionic liquid catalyzed synthesis of quinazoline-2,4(1H,3H)-diones in the presence of ambient temperature and pressure

The utilization of carbon dioxide under mild reaction conditions is an important aspect of the sustainable chemistry point of view. Herein, we prepared three bifunctional protic ionic liquids having 1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD) as a cation and an alcohol anions were prepared by simple neutralization of the super base TBD with proton donor alcohols such as hexafluoroisopropanol (HFIP), TFE (2,2,2-Trifluoroethanol) and TFA (2,2,2-Trifluoroacetic acid). These PILs were used as catalysts for chemical fixation of carbon dioxide into quinazoline-2,4(1H,3H)-diones. [TBDH+][HFIP-] protic ionic liquid (PIL) shows very good result compare to other PILs. As a bifunctional ionic liquid, it simultaneously activates 2-aminobenzonitrile as well as CO2 and shows excellent performance for the conversion of 2-aminobenzonitrile to quinazoline-2,4(1H,3H)-diones in presence of CO2 balloon pressure at 35 °C temperature. Moreover, the [TBDH+][HFIP-] PIL can be recycled up to six recycle run.

N2N N4-disubstituted quinazoline-2,4-diamines and uses thereof

Described herein are quinazoline-based compounds and formulations thereof. In some embodiments, the compounds and/or formulations thereof can be effective to inhibit and/or kill A. baumannii. Also described herein are methods of treating a subject in need thereof by administering to the subject in need thereof a quinazoline-based compound and/or formulation thereof to the subject in need thereof.